Why Influencers Use the FDA to Bash Research Peptides

The FDA's drug review budget does not come from taxpayers. It comes from the companies whose drugs are being reviewed.

This arrangement has a name: something called PDUFA, the Prescription Drug User Fee Act, which is the law that allows pharmaceutical companies to pay the FDA directly in exchange for having their applications processed. The current fee for a single drug application is $4,198,000. Those fees now fund approximately 65% of the entire human drug review budget at the FDA's Center for Drug Evaluation and Research. The companies being regulated are paying for the majority of their own regulation.

That is not a conspiracy theory. That is published in the Federal Register every year.

Now here is why that structure matters for what happens after the review. A 2018 investigation published in Science tracked FDA medical officers who left the agency between 2006 and 2019 and found that 62% of them went directly to work for the pharmaceutical industry. The FDA Commissioner from 2017 to 2019, Scott Gottlieb, left his post and joined Pfizer's board of directors that same year. The people who approve the drugs become employees of the companies whose drugs they approved.

And the influence does not stop at the revolving door. The pharmaceutical and health products industry spent $374 million on federal lobbying in 2023, which made it the single highest-spending industry in the country, and it deployed roughly three lobbyists for every one member of Congress. That is not an industry trying to survive regulation. That is an industry that has built the regulation around itself.

Understanding that system is the only context in which the peptide question makes sense.

Peptides are short chains of amino acids that your body already produces, and many of the sequences people use for research purposes, things like BPC-157 or TB-500, occur naturally in human tissue. Because they are naturally occurring sequences, they cannot be patented. A pharmaceutical company cannot own them. And because a company cannot own them, no company will spend the median cost of drug development, which a 2020 analysis in JAMA estimated at approximately $985 million per drug when you account for capitalized research costs, to push a molecule through FDA approval when any competitor can manufacture and sell that same molecule the day after approval is granted.

There is no return on that investment. So the investment never happens. And without that investment, there is no approval. And without approval, the molecule stays in a legal gray zone that makes it easy to call unsafe.

The "unsafe" label is doing a lot of work here that the science is not actually doing.

This is where the influencer argument falls apart. The argument goes: research peptides are not FDA approved, therefore they are not safe, therefore you should buy from a compounding pharmacy instead. The logic sounds clean but it only works if FDA approval is a reliable signal of safety, and the structure described above is exactly why it is not always that signal. FDA approval tells you that a company with $4 million and a team of lobbyists got their application processed. It does not tell you that every approved drug is safer than every non-approved compound, and the opioid approval history alone makes that case better than anything else could.

Compounding pharmacies operate under a different part of the FDA framework. They can legally prepare peptides that have been designated by the FDA as appropriate for compounding, which gives them a layer of regulatory cover that research chemical suppliers do not have. That cover is real and it is worth something. Compounding pharmacies are subject to inspections, sterility standards, and state pharmacy board oversight that a research supplier is not.

But here is the distinction that gets deliberately blurred. The regulatory difference between a compounding pharmacy and a research supplier is not primarily a purity or safety difference. It is a legal and business difference. A compounding pharmacy is operating inside the system, which means it is paying into the system, and the system protects it. A research chemical supplier is outside the system, which means the system has no financial interest in its survival and every incentive to cast doubt on it.

When an influencer who sells compounded peptides tells you that research chemicals are dangerous because the FDA has not approved them, they are using the structure of regulatory capture as a sales argument. They are pointing to a system built by pharmaceutical money and saying: see, this proves my product is safer. They are benefiting from the same regulatory architecture they claim to oppose in every other context.

The practical question for anyone actually trying to make decisions about research peptides is not "is this FDA approved" because you now know why that bar will never be cleared for naturally occurring sequences. The practical questions are about the supplier: do they publish independent third-party certificates of analysis, do those COAs come from accredited labs, and is the testing for purity and sterility rather than just identity. A research supplier who publishes rigorous third-party COAs is giving you more verifiable safety data than most approved supplements will ever provide.

The approval system was built to generate return on investment for companies who can own what they develop. Naturally occurring peptides were never going to fit inside that system, not because they failed the science, but because they were never compatible with the economics.

That is the only reason the FDA approval argument gets made.

---

References

1. FDA PDUFA Fee Schedule — Federal Register (published annually). FY 2024 application fee: $4,198,000.
2. FDA Budget Justification to Congress — PDUFA user fees fund approximately 65% of CDER/CBER human drug review budget.
3. Piller, C. (2018). "Is FDA's revolving door open too wide?" Science. Found 62% of FDA medical officers who left between 2006-2019 went to work for pharmaceutical industry.
4. OpenSecrets.org — Center for Responsive Politics. Pharmaceutical/health products industry spent $374 million on federal lobbying in 2023, #1 ranked industry. Approximately 1,500-1,800 registered lobbyists (roughly 3:1 ratio to members of Congress).
5. Scott Gottlieb served as FDA Commissioner 2017-2019, joined Pfizer board of directors in 2019.
6. Wouters, O.J., McKee, M., Luyten, J. (2020). "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018." JAMA Internal Medicine. Median capitalized cost: $985 million per drug.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness